Cytiva and the University of Adelaide are collaborating with BioCina, an Australian-based multi-product biologics contract development and manufacturing organisation (CDMO), to expand its facility in Adelaide to manufacture mRNA-based vaccines and therapies.
Fellow Danaher operating companies Precision NanoSystems (PNI) and the life sciences business of Pall are also contributing their technologies to complete the workflow.
The partners said that the new mRNA GMP capabilities will establish BioCina as Australia’s first CDMO that can support the manufacturing processes for pDNA, mRNA, encapsulations, and formulations.
BioCina CEO Mark W. Womack said, “We offer comprehensive supply services to biopharmaceutical customers from early-phase clinical trials to commercial production. Cytiva’s ‘from discovery to delivery’ approach perfectly echoes BioCina’s commitment to supporting our customers by providing efficient and cost-effective solutions for developing their programs as they advance towards approval and ultimately to the patients who are waiting.”
Jon Ince, the general manager of commercial for Cytiva Australia and New Zealand, added, “While Australia has a highly regarded clinical trials network, and proven track record of R&D collaborations, regional manufacturing capabilities are lagging behind other developed nations, as reported in Cytiva’s 2021 Global Biopharma Resilience Index.
“At Cytiva we are dedicated to supporting the growth of biotherapeutic manufacturing capabilities through collaborations like these with the University of Adelaide and BioCina. This supports our vision in which access to life-changing therapeutics transforms human health.”
